Table 1 Clinical trial results for PD-1 and PD-L1 inhibitors in ovarian cancer
From: Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma
Result | Agent | ||||
|---|---|---|---|---|---|
Nivolumab [19] | Pembrolizumab [17] | Avelumab [20] | Atezolizumab [23] | Durvalumab [24] | |
No. of patients | 20 | 26 | 124 | 12 | 15 |
Prior therapies | ≥4 in 55% of cases | ≥5 in 38.5% of cases | ≥3 in 65.3% of cases | ≥6 in 58% of cases | median 4 |
PD-L1+ prevalence | 80% (IC 66%) | 100% (> 1% TC) | 77% (IC 66%) | 83% (> 1% TC) | 73% (> 5% TC) |
Overall response rate | 15% | 11.5% | 9.7% | 25% | Not reported |
Median progression-free survival | 3.5 months | Not reached | 2.6 months | 2.9 months | Not reported |
Median overall survival | 20 months | Not reached | 10.8 months | 17.4 months | Not reported |